Technical Analysis for RVX - Resverlogix Corp.

Grade Last Price % Change Price Change
F 0.050 -9.09% -0.005
RVX closed down 8.33 percent on Tuesday, April 16, 2024, on 4.83 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -9.09%
Shooting Star Candlestick Bearish -9.09%
Lizard Bearish Bearish Day Trade Setup -9.09%
180 Bearish Setup Bearish Swing Setup -9.09%
Expansion Breakdown Bearish Swing Setup -9.09%
Volume Surge Other -9.09%
Doji - Bearish? Reversal -9.09%
Doji - Bullish? Reversal -9.09%
Gapped Down Weakness -9.09%
Crossed Above 20 DMA Bullish -16.67%

   Recent Intraday Alerts

Alert Time
Down 1 ATR about 2 hours ago
Bearish 180 Entry about 2 hours ago
Lizard Bearish Entry about 2 hours ago
Shooting Star Candlestick Entry about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Resverlogix Corp. Description

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Beta Clinic Biotechnology Disease RTT Medical Specialties Diseases Clinical Trial IPO Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease

Is RVX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.26
52 Week Low 0.055
Average Volume 33,319
200-Day Moving Average 0.075
50-Day Moving Average 0.061
20-Day Moving Average 0.057
10-Day Moving Average 0.057
Average True Range 0.003
RSI (14) 43.82
ADX 15.85
+DI 29.864
-DI 17.873
Chandelier Exit (Long, 3 ATRs) 0.050
Chandelier Exit (Short, 3 ATRs) 0.065
Upper Bollinger Bands 0.061
Lower Bollinger Band 0.052
Percent B (%b) 0.34
BandWidth 16.283
MACD Line -0.001
MACD Signal Line -0.002
MACD Histogram 0.0004
Fundamentals Value
Market Cap 11.98 Million
Num Shares 218 Million
EPS 0.51
Price-to-Earnings (P/E) Ratio 0.11
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.063
Resistance 3 (R3) 0.063 0.062 0.061
Resistance 2 (R2) 0.062 0.060 0.061 0.061
Resistance 1 (R1) 0.058 0.059 0.058 0.058 0.060
Pivot Point 0.057 0.057 0.056 0.056 0.057
Support 1 (S1) 0.053 0.055 0.053 0.053 0.050
Support 2 (S2) 0.052 0.054 0.051 0.049
Support 3 (S3) 0.048 0.052 0.049
Support 4 (S4) 0.048